david
sc
hui
md
unsw
fracp
frcp
paul
ks
chan
md
frcpath
b
sever
acut
respiratori
syndrom
sar
emerg
unexpectedli
pose
enorm
threat
intern
health
economi
end
epidem
juli
probabl
case
report
countri
region
mortal
sar
reemerg
small
scale
late
earli
south
china
resumpt
wild
anim
trade
activ
market
member
coronavirida
famili
classifi
group
base
serolog
recent
genet
similar
coronavirus
cov
found
wide
rang
anim
speci
includ
cat
dog
pig
rabbit
cattl
mous
rat
chicken
pheasant
turkey
whale
well
human
sar
epidem
recogn
coronavirus
caus
respiratori
tract
infect
human
previous
unrecogn
cov
detect
sar
patient
confirm
caus
agent
sar
becam
known
sarscov
retrospect
serolog
survey
suggest
crossspeci
transmiss
sarscov
variant
variou
anim
speci
human
might
occur
frequent
wet
market
high
seropreval
detect
among
anim
handler
notabl
sarslik
ill
role
mask
palm
civet
transmit
sarscov
human
first
suspect
close
relat
variant
sarscov
detect
palm
civet
dongmen
market
shenzhen
epidemiolog
evid
obtain
smallscal
outbreak
late
earli
patient
direct
indirect
contact
palm
civet
subsequ
sequenc
analysi
suggest
sarscovlik
viru
circul
among
market
mask
civet
long
period
therefor
true
natur
reservoir
sarscov
sought
cov
similar
sarscov
found
horsesho
bat
independ
research
team
bat
sarslik
cov
share
sequenc
homolog
human
civet
isol
key
differ
found
region
encod
spike
protein
critic
determin
host
rang
tissu
tropism
data
suggest
bat
could
natur
reservoir
close
ancestor
sarscov
cov
seem
use
entir
new
receptor
cross
speci
bat
palm
civet
human
addit
mask
palm
civet
bat
anim
speci
might
involv
evolut
emerg
sarscov
least
anim
speci
harbor
sarscov
certain
circumst
includ
raccoon
dog
red
fox
chines
ferret
mink
pig
wild
boar
rice
field
rat
novemb
unusu
epidem
sever
pneumonia
unknown
origin
foshan
guangdong
provinc
southern
china
high
rate
transmiss
health
care
worker
hcw
retrospect
analysi
patient
admit
chest
hospit
atyp
pneumonia
guangzhou
januari
februari
show
posit
sarscov
nasopharyng
aspir
npa
wherea
patient
posit
antibodi
sarscov
convalesc
sera
genet
analysi
show
sarscov
isol
guangzhou
origin
countri
phylogenet
pathway
match
spread
sar
part
world
physician
southern
china
visit
hong
kong
hk
februari
die
day
later
sever
pneumonia
sourc
infect
caus
subsequ
outbreak
sar
hk
sever
countri
least
hotel
guest
visitor
infect
guangdong
physician
visit
friend
stay
floor
hotel
physician
stay
briefli
intern
air
travel
visitor
spread
infect
global
within
short
period
sar
seem
spread
close
persontoperson
contact
via
droplet
transmiss
fomit
high
infect
viral
ill
shown
patient
mani
hcw
hospit
sar
within
week
result
exposur
singl
patient
visitor
hotel
admit
communityacquir
pneumonia
cap
gener
medic
ward
princ
wale
hospit
pwh
hk
superspread
event
believ
relat
use
jet
nebul
driven
air
lmin
administr
aerosol
salbutamol
index
patient
togeth
overcrowd
poor
ventil
hospit
ward
sarscov
also
detect
respiratori
secret
fece
urin
tear
infect
individu
addit
evid
suggest
sar
might
spread
airborn
transmiss
major
commun
outbreak
amoy
garden
privat
residenti
complex
hk
higher
nasopharyng
viral
load
found
patient
live
adjac
unit
block
inhabit
index
patient
amoy
garden
wherea
lower
detect
nasopharyng
viral
load
found
patient
live
away
index
patient
air
sampl
obtain
room
occupi
sar
patient
swab
sampl
taken
frequent
touch
surfac
room
nurs
station
posit
polymeras
chain
reaction
pcr
test
temporalspati
spread
sar
among
inpati
index
medic
ward
pwh
hk
also
consist
airborn
transmiss
data
support
sar
potenti
convert
droplet
airborn
droplet
transmiss
emphas
need
adequ
respiratori
protect
addit
strict
contact
droplet
precaut
manag
sar
patient
estim
mean
incub
period
day
confid
interv
ci
day
wherea
mean
time
symptom
onset
hospit
vari
day
decreas
cours
epidem
mean
time
onset
death
day
ci
day
wherea
mean
time
onset
discharg
day
ci
day
major
clinic
featur
present
includ
persist
fever
chillsrigor
myalgia
dri
cough
headach
malais
dyspnea
sputum
product
sore
throat
coryza
nausea
vomit
dizzi
diarrhea
less
common
featur
tabl
wateri
diarrhea
promin
extrapulmonari
symptom
patient
sar
week
clinic
cours
ill
intestin
biopsi
specimen
taken
colonoscopi
autopsi
reveal
evid
secretori
diarrhea
minim
architectur
disrupt
evid
activ
viral
replic
within
small
larg
intestin
reactiv
hepat
common
complic
sarscov
infect
patient
respect
increas
alanin
aminotransferas
alt
level
admiss
subsequ
cours
ill
sever
hepat
wors
clinic
outcom
chronic
hepat
b
associ
diseas
sever
sarscov
detect
cerebrospin
fluid
serum
sampl
case
statu
epilepticu
data
suggest
sever
acut
neurolog
syndrom
might
occasion
accompani
sar
older
subject
might
atyp
present
decreas
gener
wellb
poor
feed
fallfractur
case
delirium
without
typic
febril
respons
temperatur
c
contrast
young
children
year
age
often
ran
benign
clinic
cours
mimick
viral
upper
respiratori
tract
infect
wherea
teenag
tend
clinic
cours
similar
adult
report
fatal
young
children
teenag
patient
sar
pregnanc
carri
signific
risk
mortal
orchiti
report
complic
male
patient
metaanalysi
show
overal
seropreval
rate
gener
popul
hcw
although
true
incid
asymptomat
infect
remain
unknown
casecontrol
studi
involv
medic
ward
hospit
guangzhou
hk
identifi
independ
risk
factor
superspread
nosocomi
outbreak
sar
box
minimum
distanc
bed
less
perform
resuscit
staff
work
experienc
symptom
sar
patient
requir
oxygen
therapi
noninvas
posit
pressur
ventil
nppv
wherea
avail
wash
chang
facil
staff
protect
factor
experiment
studi
shown
exhal
air
particl
dispers
distanc
patient
receiv
oxygen
via
simpl
oxygen
mask
jet
nebul
least
respect
exhal
air
distanc
nppv
via
differ
face
mask
could
rang
diffus
room
contamin
face
mask
requir
connect
whisper
swivel
exhal
devic
data
import
clinic
implic
prevent
futur
nosocomi
outbreak
sar
respiratori
infect
hcw
take
adequ
respiratori
precaut
manag
patient
cap
unknown
caus
complic
respiratori
failur
within
distanc
clinic
cours
sar
gener
follow
typic
pattern
phase
viral
replic
associ
increas
viral
load
clinic
character
fever
myalgia
system
symptom
gener
improv
day
phase
ii
immunopatholog
injuri
character
recurr
fever
hypoxemia
radiolog
progress
pneumonia
reduct
viral
load
high
morbid
sar
highlight
observ
even
total
lung
field
involv
consolid
chest
radiograph
patient
would
requir
supplement
oxygen
maintain
satisfactori
oxygen
greater
wherea
patient
would
progress
acut
respiratori
distress
syndrom
ard
necessit
invas
ventilatori
support
peiri
colleagu
show
progress
decreas
rate
viral
shed
nasophargynx
stool
urin
day
day
symptom
onset
patient
serial
measur
revers
transcriptas
rt
pcr
thu
clinic
worsen
phase
ii
like
result
immunemedi
lung
injuri
result
overexuber
host
respons
could
explain
uncontrol
viral
replic
lymphopenia
lowgrad
dissemin
intravascular
coagul
thrombocytopenia
prolong
activ
partial
thromboplastin
time
increas
ddimer
increas
lactat
dehydrogenas
ldh
creatinin
phosphokinas
cpk
common
laboratori
featur
sar
absolut
lymphopenia
occur
case
sar
clinic
cours
diseas
lymphocyt
count
declin
earli
cours
sar
wherea
low
count
present
associ
advers
clinic
outcom
cell
percentag
report
neg
correl
appear
immunoglobulin
g
igg
antibodi
sarscov
retrospect
studi
toronto
found
laboratori
variabl
except
absolut
neutrophil
count
anc
show
fair
poor
discriminatori
abil
distinguish
sar
caus
cap
routin
laboratori
test
may
reliabl
diagnosi
sar
nevertheless
evalu
patient
cap
immedi
altern
diagnosi
epidemiolog
high
risk
low
anc
present
along
poor
clinic
laboratori
respons
hour
antibiot
treatment
may
rais
index
suspicion
sar
indic
need
perform
sarscov
test
score
system
may
help
identifi
patient
receiv
specif
test
influenza
sar
radiograph
featur
sar
gener
resembl
found
caus
cap
distinct
radiograph
featur
sar
includ
predomin
involv
lung
peripheri
lower
zone
addit
absenc
cavit
hilar
lymphadenopathi
pleural
effus
radiograph
progress
unilater
focal
airspac
opac
multifoc
bilater
involv
second
phase
diseas
follow
radiograph
improv
treatment
commonli
observ
case
seri
patient
develop
spontan
pneumomediastinum
patient
develop
evid
ard
period
week
incid
barotrauma
intens
care
unit
icu
admiss
high
despit
applic
lowvolum
lowpressur
mechan
ventil
highresolut
comput
tomographi
hrct
thorax
use
detect
lung
opac
case
high
index
clinic
suspicion
sar
unremark
chest
radiograph
common
hrct
featur
includ
groundglass
opacif
sometim
consolid
interlobular
septal
intralobular
interstiti
thicken
predominantli
peripher
lower
lobe
involv
fig
rout
entri
sarscov
human
respiratori
tract
mainli
via
droplet
transmiss
although
human
intestin
cell
proven
suscept
sarscov
replic
role
intestin
tract
portal
entri
remain
uncertain
similarli
although
infecti
virus
found
stool
sampl
insuffici
evid
support
fecalor
rout
transmiss
sarscov
infect
surfac
envelop
protein
sarscov
seem
play
key
role
establish
infect
determin
cell
tissu
tropism
sarscov
protein
domain
ntermin
half
contain
receptorbind
domain
rbd
ctermin
half
contain
fusion
peptid
entri
viru
requir
receptor
bind
follow
conform
chang
protein
cathepsin
lmediat
proteolysi
within
endosom
angiotensinconvert
enzym
receptor
sarscov
express
wide
varieti
tissu
includ
lung
intestin
kidney
blood
vessel
presenc
seem
sole
determin
tropism
sarscov
instanc
sarscov
found
colon
enterocyt
hepatocyt
lack
wherea
sarscov
detect
endotheli
cell
blood
vessel
smooth
muscl
cell
intestin
despit
express
data
suggest
addit
surfac
molecul
play
critic
role
establish
sarscov
infect
human
cell
dcsign
dendrit
cellspecif
intercellular
adhes
moleculegrab
nonintegrin
type
transmembran
adhes
molecul
recogn
varieti
microorgan
dcsign
express
macrophag
dendrit
cell
includ
found
skin
lung
intestin
rectum
cervix
placenta
lymph
node
howev
bind
sarscov
dcsign
lead
entri
virus
dendrit
cell
instead
facil
transfer
virus
suscept
cell
way
dendrit
cell
play
import
role
viru
dissemin
within
infect
host
lsign
dcsignr
homolog
dcsign
express
liver
lymph
node
placenta
lsign
act
conjunct
liver
lymph
node
sinusoid
endotheli
cell
ctype
lectin
lsectin
enhanc
sarscov
infect
evid
show
lsign
serv
altern
receptor
mediat
entri
sarscov
infect
establish
mechan
sarscov
caus
diseas
separ
direct
lytic
effect
host
cell
indirect
consequ
result
host
immun
respons
clinic
sar
character
pronounc
system
ill
patholog
sar
reveal
fatal
case
mainli
confin
lung
diffus
alveolar
damag
promin
featur
multinucl
syncyti
giant
cell
although
characterist
rare
seen
case
without
secondari
infect
lack
immun
respons
observ
late
termin
stage
apart
relat
endstag
multiorgan
failur
patholog
gastrointestin
tract
urinari
system
liver
organ
system
unremark
lung
intestin
tract
organ
system
support
high
level
sarscov
replic
least
mechan
direct
injuri
infect
lung
reveal
first
addit
host
receptor
mediat
entri
sarscov
probabl
contribut
diffus
alveolar
damag
neg
regul
local
reninangiotensin
system
imbal
lead
develop
diffus
alveolar
damag
data
anim
studi
suggest
diffus
alveolar
damag
seen
sar
mediat
pathway
second
direct
injuri
mechan
induct
apoptosi
sarscovencod
protein
shown
strong
induc
apoptosi
cell
line
deriv
differ
organ
includ
lung
kidney
liver
immunobiolog
clinic
sar
character
phase
cytokin
storm
intens
immun
respons
infect
reflect
increas
chemokin
cytokin
result
patholog
seen
case
run
sever
cours
ill
postmortem
lung
tissu
chemokin
cxc
motif
ligand
cxcl
interferon
ifn
induc
protein
ip
interleukin
il
found
increas
first
week
varieti
cytokineschemokin
found
increas
peripher
circul
includ
chemokin
cxc
motif
ligand
monokin
induc
gifn
cc
motif
ligand
ccl
monocyt
chemoattract
ifng
transform
growth
factor
tgf
b
monokin
induc
ifng
mig
among
increas
cytokineschemokin
increas
level
mig
first
week
onset
fever
increas
mig
second
week
associ
poor
outcom
sever
host
genet
marker
report
associ
outcom
sar
associ
hlab
sar
infect
reveal
cohort
patient
taiwan
find
reproduc
hk
patient
latter
hk
studi
hlab
found
associ
increas
suscept
wherea
protect
sarscov
infect
anoth
studi
base
patient
hk
shown
human
fc
greceptor
genotyp
associ
sever
outcom
sar
cg
gg
genotyp
found
associ
increas
suscept
sar
cohort
studi
sar
patient
hk
associ
homozygos
protect
sar
found
howev
observ
could
reproduc
studi
hk
beij
respect
treatment
ribavirin
ribavirin
nucleosid
analogu
activ
sever
virus
vitro
wide
use
treat
sar
patient
recogn
lack
clinic
respons
broadspectrum
antibiot
oseltamivir
nevertheless
known
ribavirin
signific
vitro
activ
sarscov
hemoglobin
level
patient
drop
gdl
week
oral
ribavirin
therapi
dose
g
time
day
use
ribavirin
sar
toronto
base
higher
dosag
use
treat
hemorrhag
fever
led
toxic
includ
increas
liver
transaminas
bradycardia
furthermor
addit
ribavirin
use
effect
serum
sarscov
viral
load
pediatr
sar
patient
therefor
unlik
ribavirin
alon
signific
clinic
benefit
treatment
sar
genom
analysi
sarscov
reveal
sever
enzymat
target
includ
proteas
lopinavir
ritonavir
combin
boost
proteas
inhibitor
regimen
wide
use
treatment
human
immunodefici
viru
hiv
infect
vitro
activ
sarscov
shown
lopinavir
ribavirin
mgml
mgml
respect
inhibit
vitro
cytopath
effect
achiev
concentr
mgml
lopinavir
combin
mgml
ribavirin
therefor
data
suggest
combin
might
synergist
sarscov
vivo
addit
lopinavir
mgritonavir
mg
lpvr
initi
therapi
associ
signific
reduct
overal
death
rate
vs
intub
rate
vs
compar
match
histor
cohort
receiv
ribavirin
alon
initi
antivir
therapi
report
benefici
effect
includ
reduct
corticosteroid
use
fewer
nosocomi
infect
decreas
viral
load
rise
peripher
lymphocyt
count
contrast
outcom
subgroup
receiv
lpvr
rescu
therapi
receiv
puls
methylprednisolon
mp
treatment
worsen
respiratori
symptom
better
match
cohort
improv
clinic
outcom
patient
receiv
lpvr
part
initi
therapi
may
result
peak
mgml
trough
mgml
serum
concentr
lopinavir
inhibit
viru
nelfinavir
anoth
proteas
inhibitor
commonli
use
hiv
infect
shown
inhibit
replic
sarscov
vero
cell
cultur
ifn
type
ifn
ifna
produc
earli
part
innat
immun
respons
viru
infect
type
ifn
inhibit
wide
rang
rna
dna
virus
includ
sarscov
vitro
complet
inhibit
cytopath
effect
sarscov
cultur
observ
ifn
subtyp
human
leukocyt
ifna
ifna
show
vitro
inhibitori
effect
sarscov
start
concentr
iuml
wherea
recombin
human
ifnb
potent
inhibit
sarscov
vitro
ifnb
ifng
synergist
inhibit
replic
sarscov
vitro
addit
combin
ribavirin
ifnb
shown
synergist
effect
inhibit
sarscov
anim
human
cell
line
wherea
combin
ribavirin
ifnb
ifna
also
show
synergist
effect
vitro
experiment
infect
cynomolgu
macaqu
prophylact
treatment
pegyl
ifna
significantli
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
pulmonari
damag
compar
untreat
macaqu
wherea
postexposur
treatment
pegyl
ifna
yield
intermedi
result
use
ifna
plu
corticosteroid
associ
improv
oxygen
satur
rapid
resolut
radiograph
lung
opac
lower
level
cpk
sar
patient
find
support
clinic
test
approv
ifn
treatment
sar
evid
sarscov
infect
initi
bind
sarscov
protein
highaffin
human
monoclon
antibodi
humab
term
identifi
sarscov
protein
potent
neutral
activ
vitro
vivo
humab
effici
neutral
sarscov
inhibit
syncytia
format
cell
express
protein
express
sarscov
receptor
humab
may
use
viral
entri
inhibitor
emerg
prophylaxi
treatment
sar
humab
shown
prophylact
reduc
replic
sarscov
lung
infect
ferret
abolish
shed
virus
pharyng
secret
addit
complet
prevent
sarscovinduc
macroscop
lung
patholog
vaccin
adenovirusbas
vaccin
shown
induc
strong
sarscovspecif
immun
respons
rhesu
macaqu
hold
promis
develop
protect
vaccin
sarscov
dna
vaccin
base
gene
could
induc
product
specif
igg
antibodi
sarscov
effici
mice
seroconvers
rate
dose
immun
recombin
protein
exhibit
antigen
receptorbind
abil
also
good
candid
develop
sar
vaccin
recombin
attenu
vaccinia
viru
ankara
express
protein
sarscov
elicit
protect
immun
mice
anoth
recombin
attenu
parainfluenza
viru
express
protein
also
produc
immun
follow
intranas
inocul
mice
synthet
peptid
deriv
protein
anoth
target
vaccin
develop
promis
result
obtain
vitro
vivo
rabbit
monkey
model
phase
ii
clinic
cours
patient
progress
develop
pneumonia
hypoxemia
intraven
administr
rescu
puls
mp
shown
suppress
cytokineinduc
lung
injuri
rational
could
progress
pulmonari
diseas
mediat
host
inflammatori
respons
corticosteroid
significantli
reduc
ifng
concentr
day
treatment
adult
sar
patient
induct
believ
critic
event
initi
immunemedi
lung
injuri
lymphocyt
apoptosi
use
rescu
puls
mp
clinic
progress
associ
favor
clinic
improv
resolut
fever
lung
opac
within
week
howev
retrospect
analysi
show
use
puls
mp
associ
increas
risk
mortal
adjust
ci
retrospect
studi
could
establish
whether
causal
relationship
exist
use
mp
increas
risk
death
clinician
inclin
give
puls
mp
therapi
deterior
patient
nevertheless
complic
dissemin
fungal
diseas
avascular
necrosi
bone
report
follow
prolong
corticosteroid
therapi
rescu
puls
mp
approach
avascular
necrosi
bone
found
patient
screen
use
magnet
reson
imag
risk
avascular
necrosi
patient
receiv
less
g
receiv
g
prednisoloneequival
dose
random
placebocontrol
studi
conduct
pwh
hk
show
plasma
sarscov
rna
concentr
second
third
week
ill
higher
patient
given
initi
hydrocortison
n
given
normal
salin
n
phase
clinic
cours
ill
despit
small
sampl
size
data
suggest
puls
mp
given
earlier
phase
might
prolong
viremia
thu
given
later
phase
rescu
purpos
care
design
clinic
trial
larger
sampl
size
requir
determin
optim
time
dosag
system
steroid
treatment
possibl
immunemedi
lung
injuri
sar
convalesc
plasma
donat
patient
recov
sar
contain
neutral
antibodi
may
clinic
use
treat
sar
patient
tradit
chines
medicin
glycyrrhizin
activ
compon
liquoric
root
shown
inhibit
replic
sarscov
vitro
control
studi
compar
integr
chines
western
medicin
western
medicin
alon
suggest
combin
treatment
given
phase
sar
effect
reduc
number
patient
abnorm
oxygen
satur
howev
clear
chines
medicin
compon
respons
benefit
dosag
steroid
given
group
clear
intraven
gammaglobulin
ivig
immunomodulatori
properti
may
downregul
cytokin
express
use
extens
singapor
sar
outbreak
howev
note
onethird
critic
ill
patient
develop
venou
thromboembol
includ
pulmonari
embol
despit
prophylact
use
lowmolecularweight
heparin
evid
pulmonari
embol
postmortem
case
addit
case
larg
arteri
ischem
stroke
case
given
ivig
pentaglobulin
igm
enrich
ig
administ
patient
sar
continu
deterior
despit
puls
steroid
ribavirin
use
associ
subsequ
improv
oxygen
radiograph
score
difficult
judg
effect
studi
uncontrol
puls
steroid
use
concurr
pulmonari
arteri
thrombosi
report
patient
sar
treat
ribavirin
steroid
kaletra
ivig
pentaglobulin
possibl
ivigor
pentaglobulininduc
increas
viscos
may
consequenti
patient
hypercoagul
state
sar
inhal
nitric
oxid
report
benefici
effect
sar
control
studi
compar
use
n
support
treatment
n
sever
respiratori
failur
improv
oxygen
inhal
administ
allow
ventilatori
support
discontinu
benefici
effect
persist
termin
inhal
shown
inhibit
replic
cycl
sarscov
vitro
base
data
receiv
world
health
organ
case
fatal
rate
sar
less
patient
age
year
younger
year
year
patient
age
year
older
poor
prognost
factor
sever
diseas
includ
advanc
age
chronic
hepat
b
treat
lamivudin
sever
hepat
high
initi
ldh
high
peak
ldh
high
neutrophil
count
present
diabet
mellitu
comorbid
condit
low
lymphocyt
count
present
high
initi
sarscov
viral
load
longterm
signific
impair
diffus
capac
carbon
monoxid
lung
dlco
occur
sar
survivor
pwh
cohort
month
respect
although
signific
improv
serial
chest
radiographi
observ
among
sar
survivor
still
abnorm
radiograph
score
month
despit
presenc
extens
parenchym
chang
reveal
comput
tomographi
earli
convalesc
period
sar
survivor
lung
function
test
indic
within
normal
limit
howev
exercis
abil
walk
distanc
month
ill
onset
lower
gener
popul
function
disabl
seem
proport
degre
lung
function
impair
might
caus
extrapulmonari
factor
muscl
decondit
steroid
myopathi
critic
ill
associ
polyneuropathymypoathi
also
observ
sar
survivor
report
incid
rate
avascular
necrosi
bone
among
differ
cohort
hk
rang
wherea
studi
beij
report
high
incid
sever
group
shown
persist
lung
function
abnorm
occur
less
onethird
patient
year
signific
impair
health
statu
among
sar
survivor
carer
physic
impair
long
period
isol
extrem
uncertainti
sar
ill
creat
enorm
psycholog
stress
mood
disturb
addit
steroid
toxic
person
vulner
psychosoci
stressor
might
jointli
contribut
develop
psychosi
patient
variou
form
sarscov
vaccin
evalu
inactiv
whole
viru
vaccin
immunogen
protect
anim
model
howev
approach
requir
product
larg
amount
infecti
viru
biosafeti
level
contain
facil
wide
avail
among
vaccin
manufactur
protein
sarscov
respons
receptor
bind
membran
fusion
prioriti
target
develop
subunit
vaccin
fulllength
protein
deliv
form
dna
vaccin
express
attenu
vaccinia
viru
recombin
baculoviru
system
shown
induc
cell
neutral
antibodi
respons
found
protect
challeng
studi
howev
concern
use
fulllength
protein
vaccin
harm
immun
respons
caus
liver
damag
vaccin
anim
report
possibl
enhanc
diseas
observ
vaccin
cat
infect
felin
infecti
periton
viru
also
concern
theoret
antibodi
present
low
concentr
may
form
complex
virion
taken
macrophag
via
fc
receptor
express
surfac
process
enhanc
viru
dissemin
may
lead
advers
outcom
vaccin
base
partial
protein
structur
protein
sarscov
explor
greatest
challeng
sustain
vaccin
develop
sarscov
disappear
human
antigen
chang
reemerg
strain
ever
occur
remain
unknown
sar
highli
infecti
diseas
signific
morbid
mortal
respiratori
failur
major
complic
patient
may
progress
ard
hcw
particularli
vulner
sar
viral
load
sarscov
patient
increas
peak
level
second
week
patient
hospit
sar
potenti
convert
droplet
airborn
transmiss
hcw
use
adequ
respiratori
protect
addit
strict
contact
droplet
precaut
manag
patient
sar
current
proven
effect
treatment
sar
earli
recognit
isol
stringent
infect
control
measur
key
control
highli
contagi
diseas
isol
facil
strict
droplet
contact
precaut
hand
hygien
gown
glove
mask
eye
protect
hcw
manag
patient
sar
avoid
use
jet
nebul
gener
ward
contact
trace
quarantin
isol
close
contact
import
measur
control
spread
infect
hospit
commun
presenc
sarslik
cov
horsesho
bat
implic
bat
previou
potenti
futur
emerg
novel
cov
infect
human
public
health
measur
enforc
ban
trade
wild
anim
wet
market
south
china
sarscov
infect
start
evalu
epidemiolog
highrisk
patient
communityacquir
pneumonia
immedi
altern
diagnosi
low
anc
present
along
poor
respons
hour
antibiot
treatment
may
rais
index
suspicion
sar
studi
need
examin
host
genet
marker
may
predict
clinic
outcom
